KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Total Liabilities (2016 - 2025)

Regeneron Pharmaceuticals has reported Total Liabilities over the past 17 years, most recently at $9.3 billion for Q4 2025.

  • Quarterly results put Total Liabilities at $9.3 billion for Q4 2025, up 10.66% from a year ago — trailing twelve months through Dec 2025 was $9.3 billion (up 10.66% YoY), and the annual figure for FY2025 was $9.3 billion, up 10.66%.
  • Total Liabilities for Q4 2025 was $9.3 billion at Regeneron Pharmaceuticals, up from $9.2 billion in the prior quarter.
  • Over the last five years, Total Liabilities for REGN hit a ceiling of $9.3 billion in Q4 2025 and a floor of $5.8 billion in Q1 2021.
  • Median Total Liabilities over the past 5 years was $6.9 billion (2021), compared with a mean of $7.3 billion.
  • Biggest five-year swings in Total Liabilities: soared 59.89% in 2021 and later decreased 2.72% in 2022.
  • Regeneron Pharmaceuticals' Total Liabilities stood at $6.7 billion in 2021, then decreased by 1.73% to $6.6 billion in 2022, then increased by 8.5% to $7.1 billion in 2023, then increased by 18.27% to $8.4 billion in 2024, then rose by 10.66% to $9.3 billion in 2025.
  • The last three reported values for Total Liabilities were $9.3 billion (Q4 2025), $9.2 billion (Q3 2025), and $8.3 billion (Q2 2025) per Business Quant data.